Partillion Bioscience

Partillion Bioscience, founded in 2020 and based in Los Angeles, is a private, pre-revenue platform company pioneering tools for functional single-cell analysis. Its award-winning Nanovial technology allows researchers to link a cell's secretory function (e.g., cytokine or antibody production) with its phenotype and genotype in a massively parallel, cost-effective format compatible with standard flow cytometers. The company is targeting the high-growth cell therapy and biologics discovery markets by providing a flexible reagent platform to improve the identification and characterization of potent therapeutic cells and antibodies.

Nanovial technology: nanoliter-sized, suspendable hydrogel particles that capture single cells and their secreted molecules, enabling high-throughput functional analysis (e.g., secretion) paired with downstream phenotyping and transcriptomics on standard flow cytometers.

Partillion competes with single-cell genomics companies (10x Genomics, BD, Singleron) that focus on sequencing, and with functional screening companies using microfluidics (Berkeley Lights, Cell Microsystems) or older, lower-throughput methods like ELISpot/FACS. Its key differentiation is enabling secretion-based functional sorting at scale without proprietary instruments, potentially offering a cost and flexibility advantage.